These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32170344)

  • 1. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe
    Wu Y; Li L; Wang Z; Shi J; Hu Z; Gao S; Miao W; Ma Q; Dong C; Wang F
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2613-2623. PubMed ID: 32170344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
    Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
    J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
    Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
    Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
    [No Abstract]   [Full Text] [Related]  

  • 5. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
    Facca VJ; Al-Saden N; Ku A; Reilly RM
    Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
    Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
    J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Imaging of HER2 Expression in Breast Cancer patients Using the [
    Biabani Ardakani J; Abedi SM; Mardanshahi A; Shojaee L; Zaboli E; Khorramimoghaddam A; Nosrati A; Sabahno H; Banimostafavi ES; Hosseinimehr SJ
    Clin Breast Cancer; 2023 Feb; 23(2):219-230. PubMed ID: 36581518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
    Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
    Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
    Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
    Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
    Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.
    Calzada V; Garcia F; Fernández M; Porcal W; Quinn T; Alonso O; Gambini JP; Cabral P
    World J Nucl Med; 2013 Jan; 12(1):27-32. PubMed ID: 23961253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and
    Okarvi SM; Aljammaz I
    Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Ahmadpour S; Noaparast Z; Abedi SM; Hosseinimehr SJ
    J Biomed Sci; 2018 Feb; 25(1):17. PubMed ID: 29455647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-Modality PET-SPECT Image-Guided Pretargeting Delivery in HER2(+) Breast Cancer Models.
    Hapuarachchige S; Si G; Huang CT; Lesniak WG; Mease RC; Guo X; Gabrielson K; Artemov D
    Biomacromolecules; 2021 Nov; 22(11):4606-4617. PubMed ID: 34704434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
    Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
    Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of
    Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
    Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.